Last year a jury awarded $101.2 million to Medtronic, finding that NuVasive had infringed on three of the company’s spine implant patents. Medtronic sought a permanent injunction of the verdict to prevent further sales of those products, which the district court judge denied in tentative and non-binding rulings on the post-trial motions, according to the report.
After the denial, NuVasive shares rose over 19 percent until the market closed for the day.
Related Articles on Orthopedic Devices:
Interventional Spine Receives FDA Clearance for Spine Device
Zimmer’s 2.9% Sales Increase Driven by Foreign Markets
DJO Net Sales Top $1B in 2011 Preliminary Report
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.